Introducing

Permafusion™ Technology

Introducing PermaFusion™
Technology

Click here to learn about PermaFusion™, our first-of-its-kind, proprietary mixing platform that permanently fuses liquid API’s in oil carriers.

We are embarking on a journey.

To reimagine medicine.

Our work—aimed at discovering cures—is a constant evolution and challenge to the status quo. If modern medicine is the book, we will be the next breakthrough chapter.

To challenge the status quo.

We will treat causes, not symptoms. We will endeavor incessantly to eliminate the need for our own existence.

To create better products.

Pathogens require powerful solutions, but safety does not have to be sacrificed to achieve efficacy. We have achieved, and will continue to achieve, the delicate balance between power and safety.  

"

Imagination is more important than knowledge.
Knowledge is limited. Imagination encircles the world.

– Albert Einstein

How we will get there.

Using our groundbreaking PermaFusion™ Technology.

*Liquid nanodroplets containing active ingredient suspended in petrolatum without an emulsifier.

The driving force behind multiple unique, FDA cleared therapies, as well as a vast pipeline of drug and device candidates addressing public health threats and diseases that negatively affect health and quality of life.

*Liquid nanodroplets containing active ingredient suspended in petrolatum without an emulsifier.

Watch PermaFusion™ in action

PermaFusion™ is a a revolution in topical delivery that maximizes effectiveness and minimizes risk. PermaFusion™ is a first of its kind, petrolatum-based, liquid-in-oil suspension technology that quite literally fuses water and oil. Our revolutionary technology permits the use of less active ingredient without compromising bioavailability or effectiveness. Less active ingredient means less toxicity, irritation, and/or sensitization, as has been shown in clinical testing.

Therapy areas.

We are engaged in the pursuit of drug therapies for the treatment of onychomycosis and herpes zoster opthalmicus. Commercial assets include management tools for wound care and atopic dermatitis.